URD Scope and Impact

 

Upper respiratory diseases (URDs) affect approximately 115 million Americans.1-3 Of these, estimates show 35% have allergic rhinitis, 35% have non-allergic rhinitis, and 30% have sinusitis.

URD Distribution—US1-3

URD Impact

Economic studies illustrate that allergic rhinitis (AR) can have a significant financial impact due to healthcare dollars spent on complications (including sinusitis, otitis media, asthma), as well as to lost productivity. As explained in an overview by Schoenwetter et al,4 these expenses include:

  • Between $5.9 billion and $7.3 billion in total annual direct costs (both medical and non-medical) for AR and AR with complications

  • 3.7 million work and school days lost each year due to AR

Research shows a significant impact on quality of life (QOL) due to rhinitis:

  • European data illustrate that QOL was lower for AR patients than for asthma patients5,6

  • Apart from disease severity, a patient’s perceived ability to control rhinitis can have a significant impact on his or her quality of life7

Sinusitis and other respiratory infections take a significant annual toll on healthcare resources and productivity:

  • In the 2002 National Ambulatory Medical Care Survey, the second most common diagnosis was acute upper respiratory infection8

  • Those who seek treatment for acute and chronic sinusitis combined account for over 16 million patient visits per year9,10

  • People suffering from sinusitis miss an average of four days of work each year3